Clearmind Medicine CMND 深 沪
等待开盘 08-20 09:30:00 美东时间
1.9044
-0.056
-2.84%
华盛通- 最 高1.96
- 今 开1.96
- 成交量 4.73万股
- 最 低 1.90
- 昨 收 1.96
- 总市值 282.91万
- 52周最高 524.00
- 市盈率 静 --
- 换手率 3.19%
- 52周最低 1.43
- 委 比 -91.76%
- 总股本 148.56万
- 历史最高 73200.00
- 量 比 0.24
- 振 幅 3.06%
- 历史最低 1.90
- 每 手 1
- 风险率 163.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder
All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol. The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in AUD patients. "We are pleased to ...
07-28 19:49
Clearmind Medicine Announces Ex Vivo Mucoadhesion Results For Intranasal MEAI; New Formulation Demonstrated Markedly Improved Nasal Residence Characteristics Compared With Standard MEAI Solution
Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind’s strategy of developing differentiated, next‑generation treatments for AUD and other high‑need indications. The study forms a core component of Clearmind’s intr...
07-16 21:32
Clearmind Medicine Announces Progress In Evaluating Intranasal Delivery Of Its Proprietary MEAI Treatment For Alcohol Use Disorder
The program is evaluating intranasal delivery of MEAI as a potential additional route of administration, with initial studies focused on assessing formulation feasibility and supporting the continued development of this delivery approach. AUD remains a significant unmet medical need worldwide, affec...
07-07 19:45
Clearmind Medicine Granted Additional US Patent Titled BINGE BEHAVIOR REGULATORS By USPTO
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it h...
06-29 19:56
Clearmind Medicine Awarded U.S. Patent for Binge Behavior Regulators
The patent, which refers to Clearmind's molecule MEAI (5-methoxy-2-aminoindane), covers innovative compositions and methods utilizing a pharmaceutically acceptable salt to regulate binge behaviors, including excessive drinking, eating, and gambling. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, c...
06-18 19:56
Clearmind Medicine Completes Dosing Of All 24 Participants In Groups 1 To 4 Of Part A Of Its Phase I/II Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the succe...
06-16 19:36
Why Taylor Morrison Home Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announced to acquire the homebuilder.
06-01 18:01
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers PRF Technologies (NASDAQ:PRFX) stock rose 231.0% to $4.54 during Frida...
05-30 01:06
Clearmind Medicine Announces Johns Hopkins Approval For CMND-100 Phase 1/2 Clinical Trial
The approval advances the multicenter study titled "A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Alcohol Use Disorder (AUD) Subjects: Parts A,
05-26 20:35
